anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is a multiphase, multicenter, trial that will comprehensively examine lithium in the treatment of pediatric patients with bipolar I disorder. In order to examine the treatment of bipolar disorder with lithium, this study will include four phases of treatment. The first phase, the Pharmacokinetic Phase, will include 8 weeks of Open Label treatment to determine empirically based dosing strategies for children and adolescents with bipolar disorder. Patients completing the Pharmacokinetic Phase, may be eligible to continue in the Long-Term Effectiveness Phase for a maximum of 16 weeks of lithium treatment. Subsequently, patients meeting response criteria during the Long-Term Effectiveness Phase will be eligible to continue in the Discontinuation Phase. During the Discontinuation Phase, patients will be randomized to either placebo or lithium treatment for up to 28 weeks. Finally, those subjects who experience a mood relapse during the Discontinuation Phase will be enrolled in an Open Label Restabilization Phase and treated with lithium for up to 8 weeks.
PURPOSE:To obtain an antiviral agent having low side action by using KAKKONTO (an antifebrile infusion) as an active component. CONSTITUTION:KAKKONTO produced by compounding KAKKON (root of Pueraria lobata), TAISOU (fruit of Zizyphus vulgaris), SHAKUYAKU (root of Paeonia albiflora), MAOU (stalk of Ephedra sinica), KEIHI (bark of Cinnamomum cassia), KANZOU (root of Glycyrrhiza glabra) and SHOUKYOU (rhizome of Zingiber officinale) or the extract of the KAKKONTO is used as an active component of the agent. The agent is administered at a daily rate of 3-15g of the active component in several divided doses. The amount of the active component in the preparation is generally 0.01-5mug/g of the base in the case of an agent for external use. The extraction is carried out by using various aqueous solvents, preferably water. For example, 1 pt. of KAKKONTO is extracted with 10-20 pts. of hot water and the obtained extract liquid is filtered and optionally dried to obtain the agent.
FIELD: medicine, veterinary science, pharmacy. SUBSTANCE: invention relates to pharmacological agent with antibacterial, wound-healing and anti-inflammatory effect. Invention proposes agent comprising hyaluronic acid, trimecaine and polyethylene oxide. Agent is colorless homogeneous mass of gel-like consistence, easily soluble in physiological solution and water. Pharmacological agent is used for treatment of infectious-inflammatory diseases, among them topical and general suppurative-inflammatory processes, thermal and chemical burns, trophic ulcers in chronic venous insufficiency, radiation damage of skin, scratches and for treatment of sluggish wounds of different etiology. Agent accelerates wounds healing and directs process of regenerative skin regeneration by organotypic way. EFFECT: enhanced effectiveness of agent, expanded range of agent using. 2 cl, 1 tbl, 7 ex
The recommended adult oral dosage is one 8 mg ondansetron tablet or 10 mL (2 teaspoonfuls equivalent to 8 mg of ondansetron) of Ondansetron Oral Solution, USP given twice a day. The first dose should be administered 30 minutes before the start of emetogenic chemotherapy, with a subsequent dose 8 hours after the first dose. One 8 mg ondansetron tablet or 10 mL (2 teaspoonfuls equivalent to 8 mg of ondansetron) of Ondansetron Oral Solution, USP should be administered twice a day (every 12 hours) for 1 to 2 days after completion of chemotherapy.

###  Pediatric Use

For pediatric patients 12 years of age and older, the dosage is the same as for adults. For pediatric patients 4 through 11 years of age, the dosage is one 4 mg ondansetron tablet or 5 mL (1 teaspoonful equivalent to 4 mg of ondansetron) of Ondansetron Oral Solution, USP given 3 times a day. The first dose should be administered 30 minutes before the start of emetogenic chemotherapy, with subsequent doses 4 and 8 hours after the first dose. One 4 mg ondansetron tablet or 5 mL (1 teaspoonful equivalent to 4 mg of ondansetron) of Ondansetron Oral Solution, USP should be administered 3 times a day (every 8 hours) for 1 to 2 days after completion of chemotherapy.

###  Geriatric Use

The dosage is the same as for the general population.
Disclosed herein are T Cell Receptors (TCRs) capable of binding to antigens expressed by renal cell carcinoma cells. In some examples, the TCR includes an alpha chain (e.g., SEQ ID NO: 2) and a beta chain (e.g., SEQ ID NO: 3). Also disclosed herein are vectors comprising nucleic acids encoding the disclosed TCR alpha and/or beta chains. Also disclosed herein are modified T cells expressing the TCRs. In some examples, the modified T cells are prepared by transducing T cells with a vector comprising nucleic acids encoding the TCR a and TCR β chains. In some embodiments, the method comprises transducing T cells with a vector comprising nucleic acids encoding the TCR alpha and TCR beta chains by obtaining a population of T cells, and administering to the subject a composition comprising the modified T cells to treat the subject with RCC.
This article reviews the medico-legal aspects associated with infectious diseases, highlighting their complexity and the challenges they pose. Infectious diseases cause not only an increase in morbidity and mortality in the healthcare setting but also involve complex legal issues. Healthcare-Associated Infections (HAIs) represent a growing risk with the increase in invasive procedures and can lead to patient complications and legal claims against healthcare professionals and institutions. The consequences of medical malpractice in this context are discussed, such as diagnostic delays, inappropriate use of treatments, and lack of adequate testing, which can have serious sequelae or even result in the patient's death. The review focuses on highlighting the importance of prevention, considering that healthcare-associated infections can be difficult to avoid, posing complex legal challenges. It concludes that managing infectious diseases and their legal consequences requires careful consideration of clinical practice guidelines, prevention and control strategies, and effective communication with patients. An integrated and evidence-based approach is advocated to address these challenges, emphasizing continuous education, the use of advanced diagnostic technologies, and interdisciplinary collaboration.
Skeletal muscle atrophy and dysfunction commonly accompany cardiovascular diseases such as peripheral arterial disease and may be partially attributable to systemic inflammation. We sought to determine whether acute systemic inflammation in a model of hindlimb ischaemia (HLI) could affect skeletal muscle macrophage infiltration, fibre size, or capillarization, independent of the ischaemia. Eight-week-old C57BL/6 male mice underwent either Sham or HLI surgery, and were killed 1, 3, or 7 days post-surgery. Circulating inflammatory cytokine concentrations were measured, as well as immune cell infiltration and morphology of skeletal muscle from both limbs of HLI and Sham mice. In HLI compared with Sham mice at day 1, plasma interleukin-1β levels were 216% higher (0.48 ± 0.10 vs. 0.15 ± 0.01 pg/μL, P = 0.005) and decreased by day 3. This was followed by increased macrophage presence in muscle from both ischaemic and non-ischaemic limbs of HLI mice by day 7 (7.3- and 2.3-fold greater than Sham, respectively, P < 0.0001). In HLI mice, muscle from the ischaemic limb had 21% lower fibre cross-sectional area than the non-ischaemic limb (724 ± 28 vs. 916 ± 46 μm2, P = 0.01), but the non-ischaemic limb of HLI mice was no different from Sham. This shows that HLI induces acute systemic inflammation accompanied by immune infiltration in both ischaemic and remote skeletal muscle; however, this did not induce skeletal muscle atrophy in remote muscle within the 7-day time course of this study. This effect of local skeletal muscle ischaemia on the inflammatory status of remote skeletal muscle may signal a priming of muscle for subsequent atrophy over a longer time course. HIGHLIGHTS: What is the central question of this study? Does hindlimb ischaemia-induced inflammation cause acute immune, inflammatory and morphological alterations in remote non-ischaemic skeletal muscle? What is the main finding and its importance? Hindlimb ischaemia induced systemic inflammation with subsequent neutrophil and macrophage infiltration in both ischaemic and non-ischaemic skeletal muscle; however, morphological changes did not occur in non-ischaemic muscle within 7 days. These immune alterations may have functional implications that take longer than 7 days to manifest, and subsequent or prolonged systemic inflammation and immune infiltration of muscle could lead to morphological changes and functional decline.
From 8:00 on the day before colonoscopy, the patients were given oral administration of less residue food included gruel with grain only, peeled carrot, white gourd, powdered skin, tofu, vegetable, mud and fruit. The fasting starts at 9:00 AM on the day of colonoscopy.
Patients in this group will receive Probinul neutro® a synbiotic preparation containing (perpacket): lyophilised bacteria (5×109 Lactobacillus plantarum, 2×109 Lactobacillus casei subsp. rhamnosus and 2×109 Lactobacillus gasseri, 1×109 Bifidobacterium infantis and 1×109 Bifidobacterium longum, 1×109 Lactobacillus acidophilus, 1×109 Lactobacillus salivarius and 1×109 Lactobacillus sporogenes and 5×109 Streptococcus thermophilus), prebiotic inulin (2.2 g; VB Beneo Synergy 1) and 1.3 g of tapioca-resistant starch.
Quetiapine fumarate should be initiated on Day 1 and titrated to at least 600 mg/day before Day 7 according to clinical experience and prescribe information. After Day 7, the dose of quetiapine fumarate should be adjusted between 600 mg/day to 750 mg/day at the discretion of the investigator.
BACKGROUND AND PURPOSE: Activation of the renin-angiotensin system, as a hallmark of hypertension and chronic kidney diseases (CKD) is the key pathophysiological factor contributing to the progression of tubulointerstitial fibrosis. LIM and senescent cell antigen-like domains protein 1 (LIMS1) plays an essential role in controlling of cell behaviour through the formation of complexes with other proteins. Here, the function and regulation of LIMS1 in angiotensin II (Ang II)-induced hypertension and tubulointerstitial fibrosis was investigated.
EXPERIMENTAL APPROACH: C57BL/6 mice were treated with Ang II to induce tubulointerstitial fibrosis. Hypoxia-inducible factor-1α (HIF-1α) renal tubular-specific knockout mice or LIMS1 knockdown AAV was used to investigate their effects on Ang II-induced renal interstitial fibrosis. In vitro, HIF-1α or LIMS1 was knocked down or overexpressed in HK2 cells after exposure to Ang II.
KEY RESULTS: Increased expression of tubular LIMS1 was observed in human kidney with hypertensive nephropathy and in murine kidney from Ang II-induced hypertension model. Tubular-specific knockdown of LIMS1 ameliorated Ang II-induced tubulointerstitial fibrosis in mice. Furthermore, we demonstrated that LIMS1 was transcriptionally regulated by HIF-1α in tubular cells and that tubular HIF-1α knockout ameliorates LIMS1-mediated tubulointerstitial fibrosis. In addition, LIMS1 promotes Ang II-induced tubulointerstitial fibrosis by interacting with vimentin.
CONCLUSION AND IMPLICATIONS: We conclude that HIF-1α transcriptionally regulated LIMS1 plays a central role in Ang II-induced tubulointerstitial fibrosis through interacting with vimentin. Our finding represents a new insight into the mechanism of Ang II-induced tubulointerstitial fibrosis and provides a novel therapeutic target for progression of CKD.
The Behavioral Activation for Drug Abusing Smokers (BA-DAS) treatment protocol will incorporate elements of the ST along with behavioral activation strategies, modified for smoking. Treatment will consist of five, 90-minute individual sessions, and with two booster sessions scheduled 2 and 4 weeks post quit. Participants will also receive 8 weeks of the transdermal nicotine patch.
•
     Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation (see WARNINGS and PRECAUTIONS).
•
     The use of benzodiazepines, including temazepam, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing temazepam capsules and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction (see WARNINGS).
•
     The continued use of benzodiazepines, including temazepam, may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Abrupt discontinuation or rapid dosage reduction of temazepam capsules after continued use may precipitate acute withdrawal reactions, which can be life-threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue temazepam capsules or reduce the dosage (see DOSAGE AND ADMINISTRATION and WARNINGS).
The unprecedented scale and rapidity of dissemination of re-emerging and emerging infectious diseases impose new challenges for regulators and health authorities. To curb the dispersal of such diseases, proper management of healthcare facilities and vaccines are core drivers. In the present work, we assess the unified impact of healthcare facilities and vaccination on the control of an infectious disease by formulating a mathematical model. To formulate the model for any region, we consider four classes of human population; namely, susceptible, infected, hospitalized, and vaccinated. It is assumed that the increment in number of beds in hospitals is continuously made in proportion to the number of infected individuals. To ensure the occurrence of transcritical, saddle-node and Hopf bifurcations, the conditions are derived. The normal form is obtained to show the existence of Bogdanov-Takens bifurcation. To validate the analytically obtained results, we have conducted some numerical simulations. These results will be useful to public health authorities for planning appropriate health care resources and vaccination programs to diminish prevalence of infectious diseases.
Healthcare model of wellness. A method is disclosed for monitoring the wellness state of a given human body. Measurable parameters of the physiologic metabolism of the the given human body are first sensed and then an interpretation is made of interpreted parameters of the physiologic metabolism of the given human body. This interpretation is made through the interpretation of the human brain associated with the give human body. The sensed measured parameters and the determined interpreted parameters comprise an input vector. This input vector is processed through a model of the given human body that is trained on a training data set comprised of historical measured parameters of the physiologic metabolism of the given human body that are sensed over time in conjunction with historical interpreted parameters of the physiologic metabolism of the given human body. The input vector comprises less than the set of historical measured parameters and the set of historical interpreted parameters, the output of the model providing a prediction of wellness of the given human body.
The invention belongs to the technical field of microbial secondary metabolite applications and particularly relates to the application of cochliodinol, as a chaetomium spirale strain secondary metabolite, in preparing anticoagulant drugs. The chaetomium spirale strain generates a large number of secondary metabolites based on its own unique biosynthetic pathway, so that the industrial production can be achieved. Meanwhile, the sustainable development is enabled. The TT ((i) p & < 0.001 (i)) can be significantly prolonged by the cochliodinol. Meanwhile, the FIB ((i) p & < 0.001 ( i)) can be significantly reduced by the cochliodinol. Therefore, the blood coagulation can be inhibited through prolonging the thrombin time and reducing the content of fibrinogen in the plasma. The cochliodinol has a potential value for the development of anticoagulant drugs.
Chimeric cDNA for the expression of immunogenic polypeptides include the genetic epitopic determinants for a base infectious bursal disease virus strain and at least one other infectious bursal disease virus strain. The genetic epitopic determinants encode amino acids or amino acid sequences which define epitopes bound to by previously established monoclonal antibodies. The immunogens expressed by the cDNA may be employed to provide a vaccine against a plurality of IBDV strains. The epitopic determinant of IBDV lethal strains has been detected, and an immunogen for conferring immunity with respect thereto is disclosed. Similarly, a monoclonal antibody specific for IBDV lethal strains is identified, and a vaccine for passive immunization therewith is also disclosed. Immunogens exhibiting conformational epitopes, in the form of virus-like particles, are effective in the preparation of vaccines.
PURPOSE:To obtain magnetic particles suitable for immobilizing of a living body component by adjusting a soln. mixture contg. gelatin, water soluble polysaccharide, metaphosphate and pulverous ferromagnetic material particles in a specific pH range then forming the insoluble particles within a specific grain size range by an aldehyde crosslinking agent. CONSTITUTION:Pulverous ferromagnetic material particles are dispersed in an aq. soln. contg. sodium metaphosphate and an anionic surface active agent. The dispersion is added to the mixed soln. obtd. by adding an aq. soln. of polysoccharide such as gum arabic removed of insoluble matter to an aq. soln. of gelatin adjusted with pH 9 and further mixing an aq. soln. of C2H5OH. The gelatin soln. dispersed therein with the magnetic particle is adjusted to 2.5-6pH with an aq. acetic acid and after the soln. is cooled to about 5 deg.C, a crosslinking agent such as glutaraldehyde or the like is added under stirring thereby obtaining hydrophilic and insoluble particles having 1-100mu grain size are obtd. Such particles are utilized for a solid carrier, etc. which permit easy operation such as washing and separation by taking advantage of the magnetic characteristic when a living component such as antigen, antibody or the like is going to be immobilized.
OBJECTIVE: We aimed to explore the prevalence and predictive factors of sleep-disordered breathing (SDB) in patients with cystic fibrosis (pwCF) after lung transplantation (LTX).
METHODS: We prospectively recruited adult pwCF who underwent LTX in our hospital from 2013 to 2022 and invited them for an attended overnight polysomnography (PSG) 1 year after transplantation. The apnea-hypopnea index (AHI) was the primary outcome, and SDB was defined as an AHI ≥ 5. Demographic, anthropometric, cardiometabolic, drug treatment, and pulmonary function variables were compared between pwCF with and without SDB. Multiple regression analysis was used to identify significant predictors of SDB. For a subset of participants who had available PSG before transplantation, sleep parameters were compared pre-post transplantation.
RESULTS: Sixty-two pwCF (31 females) were enrolled. Thirty participants had SDB, but only 11 of them had moderate-to-severe SDB (AHI ≥ 15). The average Epworth Sleepiness Scale (ESS) score indicated the absence of excessive daytime sleepiness. Older age (p < 0.001), male sex (p < 0.001), and smaller thoracic gas volume (p = 0.002) significantly predicted higher AHI. Comparison between pre- and post-transplantation polysomnographic data showed a significant increase in the percentage of slow wave sleep (p = 0.047), as well as a significant improvement in mean nocturnal oxygen saturation (p = 0.007). A statistically significant increase in the AHI was also observed (p = 0.047), but its clinical importance is uncertain (p = 0.476 for the increase in the ESS score).
CONCLUSIONS: We may conclude that SDB is prevalent in pwCF after LTX, but its severity is mild. Older male pwCF with greater improvement in lung hyperinflation after transplantation might be at risk for SDB and should be followed for symptoms or signs of sleep apnea.
BACKGROUND/MAIN OBJECTIVE: The main purpose of our study is to assess the effect of a lifestyle intervention combining weight control, diet and physical activity on the risk of recurrences among breast cancer patients with non-metastatic tumours. As secondary objectives we aim to assess whether the proposed intervention is able to improve the overall survival or the disease-free survival, as well as quality of life of breast cancer patients. METHODOLOGY: This multicentric randomized controlled trial aims to include 2108 women (1054 per arm), aged up to 75 years, diagnosed with a non-metastatic breast cancer (stage I, II, IIIA) in the participating centres, whose standard treatment was completed within the last 3 months. Participants will be assigned to either an intervention or a control group, and followed for five years. Patients assigned to the control arm will continue with the usual care, including standard guidelines for weight control applied in the centre. Patients in the intervention group will be involved in a lifestyle program with two components. The dietary part will aim to achieve a calorie reduction while maintaining nutritional quality; the physical activity part will include supervised sessions of moderate intensity. Data will be analyzed on an intention to treat basis using time-toevent analysis. HYPOTHESES: We expect a significant reduction in the 5-year cumulative incidence of recurrences (primary outcome) in the intervention group. Furthermore, as secondary outcomes, we expect a significant increase in overall survival and an improvement of quality of life of patients included in the intervention arm.
Infective endocarditis and infection of cardiac devices are conditions characterized by high morbidity and mortality, thus requiring a prompt diagnosis. Advanced imaging modalities are often required in the management of infectious endocarditis according to guidelines. The aim of this review is to collect and describe evidence-based knowledge about the diagnostic role and clinical usefulness of [18F]FDG PET/CT in endocarditis and cardiac device infections based on published systematic reviews and meta-analyses on this topic and on recent guidelines. [18F]FDG PET/CT is recommended only in selected cases. This imaging method has good diagnostic accuracy in detecting prosthetic valve endocarditis and cardiac device infection. Furthermore, it can identify extra-cardiac infectious foci changing the clinical management in a significant percentage of cases.